Overall Score

Revenue Growth

Kura Oncology remains a clinical-stage biotech with no meaningful commercial revenue base, so long-term growth depends on pipeline execution rather than current sales.

The company’s revenue per share is still only 0.87, indicating a very small current revenue base relative to market value.

Profitability

Margins remain deeply negative, with EBIT margin at -3.83% and net profit margin at -3.84%.

Returns on capital are still very poor, including ROA of -50.49% and ROIC of -66.95%, reflecting ongoing losses and limited operating efficiency.

Balance Sheet

Liquidity remains solid with a current ratio of 4.73 and quick ratio of 4.71.

Leverage is still modest, with debt-to-equity at 0.50 and debt-to-assets at 4.16%, while cash per share of 5.84 provides a meaningful cushion.

Cash Flow

Cash generation remains negative, with operating cash flow per share at -1.26 and free cash flow per share at -1.32.

Free cash flow yield is still negative at -12.18%, indicating the business is consuming cash rather than producing it.

Growth Efficiency

Gross margin is very high at 94.73%, which is consistent with a high-value biotech model if commercialization succeeds.

However, heavy R&D spend at 335.99% of revenue and SG&A at 174.72% of revenue show that growth is still being funded at a substantial operating loss.